[Translation] A single-center, randomized, controlled, blinded, dose-escalation, multi-stage safety, tolerability, and efficacy/pharmacokinetics study of single and continuous intravenous administration of methoxyetomidate hydrochloride for injection in healthy subjects
单次静脉给药(第一、二阶段)
主要目的:评价注射用甲氧依托咪酯盐酸盐在健康受试者中的安全性和耐受性。
次要目的:
(1)评价注射用甲氧依托咪酯盐酸盐在健康受试者中单次静脉给药的药效动力学(PD)和药代动力学(PK)特征;
(2)评价注射用甲氧依托咪酯盐酸盐在健康受试者中单次静脉给药的物质平衡及代谢转化。 持续静脉给药(第三阶段)
主要目的:评价静脉持续泵注甲氧依托咪酯盐酸盐在健康受试者中的安全性和耐受性。
次要目的:
(1)评价甲氧依托咪酯盐酸盐维持全身麻醉状态达不同时间的持续泵注剂量;
(2)评价甲氧依托咪酯盐酸盐在健康受试者中持续静脉给药的药效动力学(PD)和药代动力学(PK)特征;
(3)对比依托咪酯单次静脉注射,评价甲氧依托咪酯盐酸盐持续静脉泵注对血清皮质醇的影响。
[Translation] Single intravenous administration (Phase I and II)
Primary objective: To evaluate the safety and tolerability of methoxyetomidate hydrochloride for injection in healthy subjects.
Secondary objectives:
(1) To evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) characteristics of single intravenous administration of methoxyetomidate hydrochloride for injection in healthy subjects;
(2) To evaluate the material balance and metabolic transformation of single intravenous administration of methoxyetomidate hydrochloride for injection in healthy subjects. Continuous intravenous administration (Phase III)
Primary objective: To evaluate the safety and tolerability of continuous intravenous infusion of methoxyetomidate hydrochloride in healthy subjects.
Secondary objectives:
(1) To evaluate the continuous infusion dose of methoxyetomidate hydrochloride to maintain general anesthesia for different time periods;
(2) To evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) characteristics of continuous intravenous administration of methoxyetomidate hydrochloride in healthy subjects;
(3) To evaluate the effect of continuous intravenous infusion of methoxyetomidate hydrochloride on serum cortisol compared with single intravenous injection of etomidate.